EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Hypnotic doses of fazamorexant induced less impairment on balance and cognition than zolpidem in healthy younger and elderly individuals

Chen Xia, Huang Xingxing, Jin Lu, Wang Ruwei

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70414 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Chen Xia und 3 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Unit, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China. Hauptthemen laut MEDLINE: Zolpidem, Cognition, Hypnotics and Sedatives, Postural Balance. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Yangtze River Pharmaceutical Group Co, Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Fazamorexant is a dual orexin receptor antagonist being developed for the treatment of insomnia. This study aims to determine the dose‐exposure‐response relationship of single‐dose fazamorexant vs . zolpidem in young adult and elderly healthy Chinese volunteers.

Methods

This single‐centre, randomized, double‐blind, double‐dummy, placebo‐ and active‐controlled, 4‐period crossover study administered fazamorexant (40 mg/80 mg to young adults; 20 mg/40 mg to the elderly) and zolpidem (10 mg). Pharmacokinetics, pharmacodynamics (primary endpoint: SPV) and safety were assessed.

Results

Following a single 40 mg oral dose of fazamorexant in elderly and young adults, the geometric least‑squares mean (GLSM) values for C max were 1527.05 ng/mL (95% CI: 1268.66–1838.06) in the elderly and 1652.52 ng/mL (95% CI: 1420.41–1922.56) in young adults. The corresponding GLSM AUC 0–t values were 7815.91 h·ng/mL (95% CI: 5985.56–10205.97) and 8351.15 h·ng/mL (95% CI: 6716.38–10383.84), respectively. There was no significant pharmacokinetic difference between young adults and the elderly with fazamorexant (C max GMR 92.41% [90% CI: 75.84–112.59]; AUC 0‐t GMR 93.59% [90% CI: 70.43–124.37]). In general, high‐dose fazamorexant caused similar or less impairment vs . zolpidem in eye movements (SPV: young adults: 110.4 ± 80.1 vs . 108.3 ± 82.7 deg/sec;elderly: 145.1 ± 64.2 vs . 185.5 ± 63.0 deg/sec), choice‐reaction‐time performance, body sway and memory tests in young and elderly cohorts. The effects of low‐dose fazamorexant on these psychomotor and cognitive measurements were significantly smaller than those of high‐dose fazamorexant and zolpidem in both age cohorts. Despite of similarity in exposure, fazamorexant demonstrated larger effects on the pharmacodynamic measurements in the elderly than in young adults, suggesting an age‐related increase of pharmacological sensitivity.

Conclusions

Clinically hypnotic doses of fazamorexant induced less balance, judgement and memory impairment in healthy adults and elderly volunteers compared to the comprehensive suppression of zolpidem on the neurological system. These preliminary results suggest that fazamorexant is a potentially safer drug for insomnia. No age‐related pharmacokinetic difference was identified with fazamorexant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ZolpidemCognitionHypnotics and SedativesPostural BalanceOrexin Receptor AntagonistsHumansDouble-Blind MethodMaleAdultAgedYoung AdultFemaleCross-Over StudiesDose-Response Relationship, DrugMiddle AgedArea Under CurveAge FactorsSleep Initiation and Maintenance Disorders

Stichwörter der Autor:innen

Fazamorexantinsomniapharmacodynamicspharmacokineticszolpidem

Substanzen

ZolpidemHypnotics and SedativesOrexin Receptor Antagonists

Autor:innen und Institutionen

  • Phase I Unit, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China.
  • Hangzhou Tigermed Consulting Co., Ltd., Hangzhou, 310051, Zhejiang Province, China.
  • Yangtze River Pharmaceutical Group Co, Ltd., Taizhou, 225300, Jiangsu Province, China.

Förderung

  • Yangtze River Pharmaceutical Group Co, Ltd.

Zitieren

APA

Xia, C., Xingxing, H., Lu, J., & Ruwei, W. (2026). Hypnotic doses of fazamorexant induced less impairment on balance and cognition than zolpidem in healthy younger and elderly individuals. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70414

Vancouver

Xia C, Xingxing H, Lu J, Ruwei W. Hypnotic doses of fazamorexant induced less impairment on balance and cognition than zolpidem in healthy younger and elderly individuals. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70414

BibTeX
@article{Xia2026,
  author = {Xia, Chen and Xingxing, Huang and Lu, Jin and Ruwei, Wang},
  title = {Hypnotic doses of fazamorexant induced less impairment on balance and cognition than zolpidem in healthy younger and elderly individuals},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70414}
}
Kostenlos starten →